List of Excipients in Branded Drug BAFIERTAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Banner Life Sciences LLC	BAFIERTAM	monomethyl fumarate	69387-001	AMMONIA	2035-02-27
Banner Life Sciences LLC	BAFIERTAM	monomethyl fumarate	69387-001	BUTYL ALCOHOL	2035-02-27
Banner Life Sciences LLC	BAFIERTAM	monomethyl fumarate	69387-001	FERROSOFERRIC OXIDE	2035-02-27
Banner Life Sciences LLC	BAFIERTAM	monomethyl fumarate	69387-001	GELATIN	2035-02-27

Bafiertam Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Bafiertam is a 95 mg delayed-release capsule containing monomethyl fumarate (MMF) for adults with relapsing forms of multiple sclerosis. The product’s commercial value is concentrated in three formulation requirements: protecting MMF from gastric exposure, controlling release in the intestine, and maintaining capsule stability during storage. Excipient suppliers and generic developers have opportunities in enteric polymers, capsule technologies, moisture-control systems, and differentiated oral delivery formats. Bafiertam has no biosimilar pathway because MMF is a synthetic small molecule. [1]

What is Bafiertam and how is it formulated?

Bafiertam was approved by the U.S. Food and Drug Administration on October 2, 2020, under NDA 212227. Banner Life Sciences markets the product as a delayed-release hard gelatin capsule containing 95 mg of monomethyl fumarate. The labeled dose is 95 mg twice daily, with or without food. [1,2]

What excipients are used in Bafiertam capsules?

The Bafiertam prescribing information identifies the following inactive ingredients:

Functional category	Bafiertam excipient or material	Formulation role
Diluent	Microcrystalline cellulose	Capsule-fill bulk and powder-flow support
Disintegrants	Croscarmellose sodium; crospovidone	Promotes dispersion after the enteric coat releases
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Supports capsule filling and manufacturing
Enteric polymer	Methacrylic acid copolymer, Type C	Delays release in the stomach
Surfactants	Polysorbate 80; sodium lauryl sulfate	Wetting and dispersion
Anti-adherent or coating aid	Talc	Coating-process control
Plasticizer	Triethyl citrate	Improves enteric-film flexibility
Color and opacity agents	Titanium dioxide and capsule-shell colorants	Product identification and light protection
Capsule shell	Hard gelatin	Unit-dose oral delivery

The formulation is built around an enteric barrier rather than a conventional immediate-release capsule. Methacrylic acid copolymer Type C is the key release-controlling excipient. Triethyl citrate helps reduce brittleness and cracking in the polymer film, while talc supports coating performance.

Why is the enteric coating commercially important?

MMF and related fumarate products can cause gastrointestinal adverse events. An enteric coating can reduce direct exposure of the active ingredient to the stomach and shift drug release toward the small intestine. The coating therefore has both a technical and commercial function.

A substitute formulation must preserve:

• Acid resistance during gastric residence.
• Prompt release after intestinal pH increases.
• Consistent dissolution across fed and fasted conditions.
• Adequate stability under humidity and temperature stress.
• Capsule integrity during packaging, shipping, and handling.

The main development risk is that a lower-cost polymer substitute may change dissolution or pharmacokinetics. A generic or licensed alternative would need to demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. [3]

Which excipient technologies could improve Bafiertam?

Commercially relevant alternatives include:

1. Methacrylate copolymer systems. Alternative grades of anionic methacrylate polymers could provide comparable pH-triggered release while reducing dependence on a single supplier or improving coating efficiency.

2. Aqueous enteric dispersions. Aqueous polymer systems can reduce solvent-handling requirements. They require tight control of spray rate, inlet temperature, atomization, and film curing.

3. Ready-to-use coating systems. Pre-formulated systems containing polymer, plasticizer, pigment, and anti-tacking agents can shorten development time for generic and lifecycle products.

4. Low-moisture capsule systems. Hard gelatin capsules and powder blends can be sensitive to moisture migration. Hydroxypropyl methylcellulose capsules, high-barrier bottles, and desiccant packaging could reduce stability risk.

5. Co-processed excipients. A co-processed filler-disintegrant system may improve powder flow, content uniformity, and automated capsule filling, particularly if the formulation uses a high proportion of low-dose MMF relative to excipient mass.

What FDA regulatory status does Bafiertam have?

Bafiertam is an FDA-approved prescription drug for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is administered orally as a delayed-release capsule. [1]

The approval was supported by clinical and regulatory data for MMF. Because MMF is a small molecule, follow-on developers would generally pursue an abbreviated new drug application rather than a biosimilar application. The principal regulatory issues are likely to involve:

• Active ingredient sameness.
• Delayed-release performance.
• Comparative dissolution.
• Bioequivalence.
• Capsule strength and labeling.
• Stability and impurity control.
• Food-effect performance where required.

Does Bafiertam have biosimilar risk?

No. Biosimilars apply to biological products. Bafiertam contains chemically synthesized monomethyl fumarate and is exposed to conventional generic-drug competition rather than biosimilar competition.

The competitive distinction matters commercially. A generic developer can seek approval through the ANDA pathway if it can meet sameness, equivalence, and quality requirements. An excipient supplier that helps a developer achieve equivalent release and bioavailability can participate without owning the active pharmaceutical ingredient.

When does Bafiertam lose exclusivity?

Bafiertam’s regulatory exclusivity and patent exclusivity are separate.

FDA approval in October 2020 established the product’s approval date. Any Hatch-Waxman exclusivity period depends on the legal basis of the approval and FDA’s Orange Book records. Patent expiry depends on issued claims, patent-term adjustment, patent-term extension, terminal disclaimers, and any litigation or settlement affecting generic entry. [2,4]

A commercial assessment should distinguish the following dates:

Exclusivity or barrier	Relevance to Bafiertam
FDA approval date	October 2, 2020
Regulatory exclusivity	Determined by FDA approval basis and Orange Book records
Listed formulation patents	Must be assessed against current Orange Book entries
Method-of-use patents	May affect labeling and skinny-label strategy
Patent-term adjustment or extension	Can change nominal expiry
Paragraph IV litigation	Can delay or accelerate generic entry
Settlement agreements	May establish an authorized or licensed entry date

The practical opportunity for excipient developers increases as regulatory exclusivity expires and generic applicants begin filing. Patent protection may still cover specific formulations or methods, but an alternate excipient composition can avoid infringement if it does not practice valid asserted claims.

What patents protect Bafiertam’s formulation?

Bafiertam’s relevant intellectual-property analysis should separate active-ingredient patents from product-specific formulation and method-of-use patents. The strongest formulation claims would generally cover combinations involving:

• MMF.
• Delayed release.
• Specific enteric polymers.
• Defined dissolution profiles.
• Capsule compositions.
• Treatment of relapsing multiple sclerosis.

An excipient change can have direct freedom-to-operate value. Replacing a claimed polymer grade, altering the coating architecture, changing the capsule shell, or modifying the dissolution profile may reduce exposure to formulation claims. The change must still satisfy FDA equivalence requirements.

Are method-of-use patents a major barrier?

Method-of-use patents can restrict a generic label even where the formulation is technically non-infringing. The relevant risk is whether an applicant’s proposed labeling induces use covered by an unexpired claim. A section viii statement or skinny-label approach may be available only if the protected indication or dosing instruction can be carved out without compromising the approved generic label.

For Bafiertam, the central technical value proposition is the MMF active moiety and delayed-release delivery. Formulation developers should therefore assess both composition claims and treatment claims before selecting a launch strategy.

What generic entry risks exist for Bafiertam?

Generic competition is technically feasible but not frictionless. The main barriers are:

Delayed-release bioequivalence

A capsule that matches the active ingredient strength but releases MMF at the wrong pH or rate may fail comparative performance requirements. Dissolution testing should cover acidic and intestinal media, multiple time points, agitation conditions, and method robustness.

Excipient variability

Enteric polymers can differ by viscosity, neutralization behavior, particle size, and film formation. These differences can affect release, especially after storage. Suppliers with strong lot-to-lot control can create a commercial advantage.

Gastrointestinal tolerability

An alternative that releases too early may increase gastric exposure and worsen tolerability. A formulation that releases too slowly may reduce or delay systemic exposure.

Manufacturing scale-up

Laboratory coating performance does not guarantee commercial-scale performance. Pan loading, spray distribution, drying, curing, and capsule handling can alter dissolution. Contract development and manufacturing organizations with delayed-release expertise are potential partners.

How does Bafiertam compare with Tecfidera and Vumerity?

Product	Active ingredient	Dosage form	Typical maintenance dose	Commercial formulation issue
Bafiertam	Monomethyl fumarate	Delayed-release capsule	95 mg twice daily	Direct MMF delivery with enteric protection
Tecfidera	Dimethyl fumarate	Delayed-release capsule	240 mg twice daily	DMF conversion to MMF; gastrointestinal tolerability
Vumerity	Diroximel fumarate	Delayed-release capsule	462 mg twice daily	Prodrug conversion and differentiated tolerability profile
Generic dimethyl fumarate	Dimethyl fumarate	Delayed-release capsule	Generally aligned with Tecfidera labeling	Price competition and delayed-release equivalence

Bafiertam’s differentiator is direct administration of MMF rather than a fumarate prodrug. Its excipient strategy must therefore support direct intestinal delivery while maintaining a commercially acceptable capsule size, dissolution profile, and shelf life.

What commercial opportunities exist for excipient suppliers?

Enteric polymer supply

The most direct opportunity is supply of methacrylic acid copolymers and compatible plasticizer systems. Suppliers can compete on:

• Cost per coated capsule.
• Aqueous processing.
• Film flexibility.
• Low-temperature curing.
• Batch consistency.
• Regulatory documentation.
• Global availability.

Stability and packaging systems

Moisture-control products can support longer shelf life and reduce manufacturing losses. Opportunities include high-barrier blister films, desiccant-integrated bottles, low-moisture capsule shells, and packaging designs that limit oxygen and humidity ingress.

Generic development packages

Excipient companies can provide formulation kits combining polymer, plasticizer, anti-tacking agent, and process instructions. A package that accelerates dissolution matching and scale-up can be more valuable than a commodity excipient alone.

Patient-centric reformulation

Potential lifecycle opportunities include smaller capsules, alternative capsule shells, reduced pill burden, and packaging designed for adherence. Any reformulation would need to preserve delayed-release performance and meet FDA requirements for the relevant application type.

Geographic expansion

The strongest near-term markets are the United States and other jurisdictions with established generic pathways for delayed-release oral products. Europe, Canada, Japan, and selected emerging markets may offer opportunities for suppliers that can provide multi-region regulatory files, compendial support, and local manufacturing continuity.

How strong is Bafiertam’s formulation estate?

The formulation estate is strongest where it combines a defined delayed-release architecture with dissolution, stability, or treatment claims. Its practical strength depends on the scope and remaining term of issued patents, Orange Book listings, prosecution history, and the ability of generic applicants to design around the claims.

From an excipient perspective, the estate is less resistant to competition if protection depends on a broad functional result, such as delayed intestinal release, rather than a narrow claim requiring a particular polymer, ratio, coating thickness, or dissolution window. Alternative enteric polymers and coating architectures can create design-around opportunities.

What litigation and settlement issues affect Bafiertam?

Paragraph IV litigation, if filed against Bafiertam patents, could create a 30-month stay for an ANDA under the Hatch-Waxman framework, subject to statutory conditions and court developments. The commercial effect would depend on the patents asserted, the filing date, claim construction, and any settlement terms. [5]

A settlement may provide:

• An agreed generic launch date.
• An authorized-generic arrangement.
• A license to specific formulation technology.
• Restrictions on the generic’s label or manufacturing process.
• A negotiated resolution without a final invalidity decision.

Patent and litigation databases should be reviewed before committing to a Bafiertam excipient program. The key diligence target is whether a proposed coating system practices an issued claim, not whether it resembles the marketed product.

Key Takeaways

• Bafiertam is a 95 mg delayed-release MMF capsule approved by FDA in October 2020.
• Methacrylic acid copolymer Type C is the central release-controlling excipient.
• The highest-value technical opportunities are enteric coating optimization, moisture protection, capsule-shell alternatives, and generic bioequivalence support.
• Bafiertam faces generic, not biosimilar, competition.
• Excipient substitution may create freedom-to-operate value, but the proposed composition must be tested against issued formulation claims.
• Commercial differentiation is possible through lower-cost aqueous coating systems, improved stability, smaller capsules, and integrated development packages.
• Generic-entry timing depends on current Orange Book listings, patent term, Paragraph IV litigation, and settlement agreements.

FAQs

Can Bafiertam use a different enteric polymer in a generic product?

Yes, subject to pharmaceutical equivalence, bioequivalence, dissolution performance, stability, and freedom-to-operate analysis. A different polymer can support a design-around strategy if it achieves equivalent release without practicing valid patent claims.

Which excipient is most important for Bafiertam performance?

The enteric methacrylic acid copolymer is the most important excipient because it controls protection from gastric conditions and intestinal release. Triethyl citrate and talc also affect coating flexibility and process performance.

Is Bafiertam suitable for an authorized-generic strategy?

Potentially. An authorized-generic strategy would depend on the brand owner’s commercial plans, licensing terms, manufacturing capacity, and remaining regulatory or patent barriers.

Could hydroxypropyl methylcellulose capsules replace gelatin capsules?

Potentially, but the replacement would require evaluation of moisture transfer, mechanical strength, dissolution, fill compatibility, stability, and bioequivalence. Capsule-shell substitution can affect the complete delayed-release system.

What is the largest commercial risk for a Bafiertam excipient supplier?

The largest risk is technical failure to reproduce the reference product’s delayed-release and pharmacokinetic profile. A lower-cost excipient that creates early release, delayed absorption, or stability failure is unlikely to support regulatory approval.

References

1. U.S. Food and Drug Administration. (2020). Bafiertam (monomethyl fumarate) delayed-release capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2020). FDA approves new treatment for multiple sclerosis.
3. U.S. Food and Drug Administration. (2018). M9 biopharmaceutics classification system-based biowaivers: Guidance for industry.
4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications.